You are here: Industry Insights > Astellas

News List

Glenmark Pharma gets ANDA approval for Tacrolimus Capsules expresspharma
November 12, 2020
It is the generic version of Prograf Capsules of Astellas Pharm.
Astellas to acquire iota Biosciences following R&D partnership pharmatimes
October 19, 2020
Japanese pharma Astellas will acquire bioelectronics firm iota after announcing a research and development agreement last year.
Astellas, Seagen Announce Positive Results from PADCEV Trial for Urothelial Cancer americanpharmaceuticalreview
October 16, 2020
Astellas Pharma and Seagen announced positive topline results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201.
Astellas Establishes Global Patient Centricity Leadership Structure americanpharmaceuticalreview
October 09, 2020
Astellas announced the structure and operating model for its global Patient Centricity organization designed to support the development of innovative health solutions.
NICE publishes guidance on Astellas' Xospata pharmatimes
August 18, 2020
The National Institute for Health and Care Excellence has now published final guidance backing NHS use of Astellas' Xospata as monotherapy for adults with relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia (AML).
Astellas, CytomX form T-cell engaging cancer antibodies partnership pharmatimes
March 27, 2020
Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer.
Astellas, Adaptimmune to Co-Develop, Commercialize CAR-T and TCR T-Cell Therapies americanpharmaceuticalreview
January 19, 2020
Astellas Pharma, through its wholly-owned subsidiary Universal Cells, and Adaptimmune Therapeutics have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.
Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer pharmaceutical-business-review
January 17, 2020
Astellas Pharma has signed a deal worth up to $897.5m with Adaptimmune Therapeutics to co-develop and co-commercialise stem-cell derived allogeneic CAR-T and TCR T-cell therapies for cancer.
Astellas Completes Acquisition of Audentes Therapeutics americanpharmaceuticalreview
January 16, 2020
Astellas Pharma has successfully completed the previously announced acquisition of Audentes Therapeutics, through a tender offer by its indirect wholly-owned subsidiary Asilomar Acquisition for all of the issued and outstanding shares of common stock of .
FDA approves Astellas’ Mycamine supplemental new drug application pharmaceutical-technology
January 13, 2020
The US Food and Drug Administration (FDA) has approved Astellas Pharma’s supplemental New Drug Application (sNDA) for Mycamine (micafungin for injection).

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page